Novo Nordisk AS (MEX:NVON) FFO


MEX:NVON Novo Nordisk AS MEX:NVON
76 GF Score
Price MXN831.50
GF Value MXN2,387.52
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS FFO?

FFO (Funds from operations) only applies to REITs.

MEX:NVON
76GF Score
Novo Nordisk AS MEX:NVON
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (MEX:NVON) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of MXN831.50 is trading 65.2% below its estimated GF Value™ of MXN2,387.52. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for MEX:NVON:

  • FFO:
  • GF Value™: MXN2,387.52 vs. price of MXN831.50 (65.2% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the MEX:NVON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
76GF Score

Get the complete analysis for MEX:NVON

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN831.50
Price
MXN2,387.52
GF Value